Table 2 Efficacy and Safety Outcome
Variables | Enoxaparin 80 (53.3%) | Rivaroxaban 70 (46.7%) | p-value |
|---|---|---|---|
Primary Efficacy Outcomes | |||
VTE Recurrence | 0.42 | ||
No | 72 (90.0%) | 60 (85.7%) | |
Yes | 8 (10.0%) | 10 (14.3%) | |
• DVT recurrence | 0.11 | ||
Proximal | 3 (100.0%) | 6 (100.0%) | |
Distal | 0 (0.0%) | 0 (0.0%) | |
• PE recurrence | 0.07 | ||
Central | 5 (100.0%) | 2 (50.0%) | |
Sub segmental | 0 (0.0%) | 2 (50.0%) | |
Primary Safety Outcomes | |||
Safety outcome | 0.65 | ||
No bleeding | 59 (73.8%) | 55 (78.6%) | |
Minor bleeding | 12 (15.0%) | 7 (10.0%) | |
Major bleeding | 9 (11.2%) | 8 (11.4%) | |